Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Phylos Bioscience

Explore full profile

Cannabis genetics company that empowers growers of all sizes to produce high quality cannabis in a cost-effective way

Portland, United StatesFounded 2014Food
Valuation $25–50M Last recorded · 2023
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Phylos Bioscience and the history behind them.

About Phylos Bioscience

Phylos Bioscience operates at the intersection of agricultural science and data technology, focusing specifically on the cannabis and hemp industries. Founded in 2014 by Nishan Karassik and Mowgli Holmes, the company initially aimed to create a comprehensive genetic map of the cannabis plant, similar to a 23andMe for cannabis. Nishan Karassik's background in technology and sustainable agriculture, combined with Mowgli Holmes's expertise as a molecular biologist, provided the foundational knowledge for this endeavor. Holmes, who holds a PhD from Columbia University, was driven by the potential to apply modern genomic science to a plant with a long, yet poorly documented, history of cultivation.

The company's core business revolves around providing genomic testing and data services to cultivators, breeders, and researchers within the cannabis market. Its primary offering is a suite of genetic tests that can identify a plant's lineage, cannabinoid and terpene profiles, and sex. This information empowers growers to make more informed decisions, optimize their cultivation practices for desired traits, and protect their intellectual property. The business model is primarily service-based, generating revenue from the sale of these testing kits and the associated data analysis. Phylos serves a diverse clientele, ranging from large-scale commercial growers to smaller craft producers and research institutions.

A significant development in the company's trajectory was the introduction of its own proprietary cannabis seeds. This move represented a strategic pivot from being purely a data and testing provider to also becoming a direct supplier of plant genetics. This vertical integration allows Phylos to leverage its vast genetic database to breed new varieties with specific, commercially desirable characteristics, such as high yields or specific chemical profiles. This expansion into seed production provides a new and substantial revenue stream, positioning the company as a key player in the supply chain for cannabis cultivation. The company's database, known as The Phylos Galaxy, has been a central part of its identity, mapping the genetic relationships between thousands of cannabis strains and making this information accessible to its clients.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2014
Headquarters
Portland, United States
Employees
49
Open positions
None listed
Dealroom signal
72.6/100
Industry
Food
Sub-industry
AgriTech
Sector
Food, Testing, Biotechnology, Research and Development, Cannabis, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
CONVERTIBLE✓Equity / VC Jul 2024 $1M — OrganiGram ↗
CONVERTIBLE✓Equity / VC Nov 2023 $2.8M — OrganiGram ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Phylos Bioscience website traffic

Latest recorded traffic for Phylos Bioscience is 17K monthly website visits, up 153.7% over the last three months. Phylos Bioscience's team grew 2.1% over the past year.

Latest monthly visits17K 3-month web change+153.7% 1-year team growth+2.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • OrganiGram

Series B and later4 investors entered at this stage

Other known investors1 additional known investor

  • Big Rock
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Phylos Bioscience on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Phylos Bioscience’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.